The critical role of RANKL in osteoporosis is now well-established by the efficacy of denosumab, a human monoclonal anti-RANKL antibody, that specifically inhibits the interaction between RANKL and RANK, in postmenopausal osteoporosis (10). The gene discussed is TNFSF11; the disease is postmenopausal osteoporosis.